Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0NDLFN
ADC Name
CN105051032B ADC-I-33
Synonyms
CN105051032B ADC-I-33
   Click to Show/Hide
Organization
Celltrion, Inc.?
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer
Investigative
.
Drug-to-Antibody Ratio
4.41
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
CN105051032B_ADC-I-33 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
2.89
ng/mL
CVCL_0179
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 2.89 ng/mL Positive HER2 expression (HER2+++/++)
Method Description
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.

   Click to Show/Hide
In Vitro Model Invasive breast carcinoma BT-474 cells CVCL_0179
References
Ref 1 Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same.